This study investigated the effect of glutamine, an amino acid, glycemia, glucagon-like peptide-1 (GLP-1) and insulin in participants with type 2 diabetes.
In this study, we investigated the effect of glutamine, an amino acid, on glycemia and on GLP-1 and insulin in participants with type 2 diabetes. Preliminary data published by our group suggests that glutamine is a strong determinant of GLP-1 secretion in vitro. We tested the hypothesis that glutamine lowers postprandial blood glucose and investigated whether the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin modifies this effect.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
22
Glutamine 30g +sitagliptin 100mg
Glutamine 30g +placebo (matching sitagliptin 100 mg)
Clinical Research Facility
Sydney, New South Wales, Australia
Postprandial Glucose Area Under the Curve (AUC)
The area under the curve (AUC) of the postprandial glucose following a meal challenge
Time frame: 0 to 180 minutes
Fructosamine
The blood concentration of the glycemic control marker fructosamine
Time frame: 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.